SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the Medical Product 1.1 Product Name: SITAPRIL M 50/500 (Sitagliptin 50 mg and Met
![These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006 These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=januvia-04.jpg&id=723719)
These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006
![Pharmacokinetic–Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers - Kim - 2013 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library Pharmacokinetic–Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers - Kim - 2013 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6eafbafb-a559-4fd1-ba8b-3a02ae3ba5ed/bcpt12068-fig-0003-m.jpg)
Pharmacokinetic–Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers - Kim - 2013 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
![Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers - GaBI Journal Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers - GaBI Journal](http://gabi-journal.net/wp-content/uploads/GJ-2023-1-p3-Tab2.jpg)